References Adams M, Smith PD, Martin D, Thompson JR, Lodwick D, and Samani NJ (1996)
Bournat JC, Brown CW (2010) Mitochondrial dysfunction in obesity
This gap has catalyzed significant R&D investment in muscle-sparing adjuncts, including myostatin inhibitors and ActRII pathway modulators that could be combined with GLP-1 agonists to preserve lean mass while maintaining fat loss efficacy
It's a hopeful story, which is, frankly, what people need, says Arif Kamal, an oncologist specializing in breast cancer as well as chief patient officer at the American Cancer Society
10.1016/j.ibror.2019.07.1721 25 BassoM.MassignanT.SamengoG.CheroniC.De BiasiS.SalmonaM.et al